Track record · closed signal

Innoviva Inc (INVA) — closed signal from March 20, 2026

Partial Published before the outcome was known, scored automatically when the window closed on June 18, 2026 — +1.9% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted
$22.07 Published $25.16 Target $22.49 Window close $24.45 Peak
$21.25 – $22.75Entry zone — fair-value band
$22.07Published — price the day we called it
$25.16Target — the price the thesis aimed for
$24.45Peak — highest point inside the window, not a realized return
$22.49Window close — end-of-window price, context only

What happened

Partial

Reached 77% of the predicted growth at its peak, without hitting the target.

At window close
+1.9%
realized, from the publication price to the last close inside the window
Peak gain
+10.8%
peak, from the publication price — not a realized return
S&P 500, same window
+15.4%
SPY over the identical days, dividend-adjusted
Window close
$22.49
last close inside the window, ended June 18, 2026
Peak price
$24.45
peak on April 20, 2026 — not a realized return
Days to target
—

The thesis — published March 20, 2026

Predicted growth
+14%
over the measurement window
Target price
$25.16
the price the thesis aimed for
Entry zone
$21.25 – $22.75
the fair-value band we waited for
Price at publication
$22.07
published March 20, 2026
Confidence
70%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Recent company news connects a share buyback plan, a higher price target, and a clearer plan for product revenue growth. Shares trading near their short-term 20-day trend suggest they are not overstretched, which could allow a measured rise if cash generation proves consistent. The thesis relies more on company-specific strength than broad market support.

Primary drivers

  • Share buyback lowers downside risk and signals management confidence
  • Product and royalty mix gives company-specific paths for growth
  • Healthy cash on the balance sheet reduces need for outside funding
  • Higher target helped reinforce the narrative of a turnaround

How it played out

INVA: rose 10.8% but missed the target

Lyra published INVA at $22.07 with expected growth of 14% and a $25.16 target. The thesis pointed to the share buyback, the product and royalty mix, available cash, and a higher price target. It expected these company-specific factors to support a measured rise if cash generation remained consistent.

The shares reached a peak of $24.45 on April 20, a gain of 10.8%. That peak stayed below the $25.16 target, so the target was never reached. INVA ended the window at $22.49. The thesis partially played out because the price rose toward the target but gave back most of that gain before the window closed.

What happened during the window

On May 6, Innoviva reported first-quarter revenue of $98.0 million and net product sales of $41.4 million. On June 16, its subsidiary announced an exclusive distribution and licensing agreement with Dr. Reddy's for XACDURO in selected international markets.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.